Holliston

Life sciences firm Harvard Apparatus Regenerative Technology of Holliston, which is developing bioengineered organs for life-threatening conditions, lost nearly $4.5 million during the second quarter as the firm pushes toward preclinical trials for a new generation of products, the company reported.

Life sciences firm Harvard Apparatus Regenerative Technology of Holliston will work with a Connecticut hospital to develop a way to fix or replace a child's esophagus to treat life-threatening conditions, the Holliston firm announced Monday.

<i>(UPDATED Friday, July 31 to correct company name)</i> Holliston-based Harvard Bioscience reported Thursday that the second quarter of 2015 saw revenue rise to $28.8 million.

James McGorry will be the next CEO of Holliston-based Harvard Apparatus Regenerative Technology (HART), the company announced today.

Clinical research company Veristat of Holliston has opened a new office in the Bay Area that will house the company's West Coast operations, it announced Monday.

Twenty-seven Central Massachusetts companies are among nearly 200 companies in the Bay State that have been awarded state-funded workforce training grants.

Clinical research company Veristat will move its headquarters from Holliston to Southborough this summer as it meets higher demand from its pharmaceutical and biotechnology clients, the company said Tuesday

It's our annual list of 10 change makers from MetroWest who are making a difference in their businesses, industries and communities.

There is a science to the work of Harvard Bioscience CEO Jeffrey Duchemin. And acquisitions are an...

Holliston-based Harvard Apparatus Regenerative Technology, or HART, reported Thursday that the first quarter of 2015 saw a reduction in net loss compared with the first quarter of 2014.